MarketPulse

clinical remission

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Eupraxia Pharmaceuticals Inc.

Eupraxia's EE Drug Hits Key Milestone With 90% Tissue Improvement in Phase Data

Eupraxia Pharmaceuticals reports positive Phase 1b/2a data for EP-104GI in eosinophilic esophagitis, showing 90% tissue improvement and strong safety profile.
EPRXbiotechdrug delivery
GlobeNewswire Inc.GlobeNewswire Inc.··Immatics N.V.

Immatics' Experimental Cancer Therapy Achieves Remission in Teen with Advanced Tumor

Immatics' PRAME-directed TCR therapy achieves deep remission in advanced pediatric cancer patient, validating engineered T-cell approach in solid tumors.
MRNAIMTXpediatric cancercell therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Spyre Therapeutics, Inc.

Spyre's SPY001 Shows Promise in Ulcerative Colitis With Strong SKYLINE Trial Data

Spyre Therapeutics reports positive Phase 2 results for SPY001 in ulcerative colitis, meeting primary endpoints with significant histopathology improvements and favorable safety.
SYREulcerative colitisclinical remission
BenzingaBenzinga··Vandana Singh

AbbVie's Skyrizi Posts Strong Remission Data, Challenges J&J in Crohn's Market

AbbVie's Skyrizi achieved 55% remission rate in Crohn's patients versus 30% placebo, strengthening competitive positioning against Johnson & Johnson's Tremfya.
JNJABBVimmunologyCrohn's disease
BenzingaBenzinga··Vandana Singh

Takeda Stock Falls Despite Positive Pediatric UC Data for Entyvio

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.
TAKPhase 3 trialpharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Sanofi And Teva

Sanofi, Teva Report Sustained Efficacy for TL1A Inhibitor in IBD Phase 2b Trial

Sanofi and Teva's duvakitug showed sustained efficacy treating ulcerative colitis and Crohn's disease in a Phase 2b trial, supporting advancement to Phase 3 development.
SNYTEVAmonoclonal antibodyinflammatory bowel disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Duvakitug Shows Sustained Remission in Phase 2b Trial for Inflammatory Bowel Disease

Teva and Sanofi's duvakitug showed sustained remission in phase 2b trial for inflammatory bowel disease, with remission rates of 41-58% depending on condition and dosage.
SNYTEVAmonoclonal antibodyinflammatory bowel disease